ANGPTL4 T266M variant is associated with reduced cancer invasiveness

Zhen Wei Tan1, Ziqiang Teo1, Carol Tan1

  • 1School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.

Insights

The T266M mutation in C-terminal Angiopoietin-like 4 (cANGPTL4) impairs tumor cell binding to integrin α5β1, affecting cancer progression and energy metabolism.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Angiopoietin-like 4 (ANGPTL4) is a secretory protein implicated in cancer and metabolic processes.
  • Point mutations in the C-terminal ANGPTL4 (cANGPTL4) have been identified but their functional significance remains unclear.

Purpose of the Study:

  • To investigate the functional impact of the T266M mutation in cANGPTL4 on tumor characteristics and cellular processes.
  • To compare tumors with wild-type (wt) cANGPTL4 and T266M cANGPTL4.

Main Methods:

  • Comparative analysis of tumor characteristics with wt cANGPTL4 and T266M cANGPTL4.
  • Assessment of T266M cANGPTL4 binding affinity to integrin α5β1.
  • Evaluation of downstream signaling, tumor cell proliferation, anoikis resistance, migration, and energy metabolism.

Main Results:

  • T266M cANGPTL4 exhibited reduced binding affinity to integrin α5β1 compared to wt cANGPTL4.
  • Mutant tumors showed impaired proliferation, anoikis resistance, and migratory capability.
  • Reduced adenylate energy charge and altered Glut2 expression were observed in tumors with T266M cANGPTL4.

Conclusions:

  • The T266M mutation in cANGPTL4 affects integrin binding, leading to significant alterations in tumor cell behavior and energy metabolism.
  • These findings provide insights into the role of cANGPTL4 mutations in cancer progression and metabolic dysregulation.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54